Response to: 'Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis' by Oiwa

Comment

Josef S Smolen. Ann Rheum Dis. 2018 Jul.

. 2018 Jul;77(7):e36.

doi: 10.1136/annrheumdis-2017-212229. Epub 2017 Sep 28.

No abstract available

Keywords: disease activity; rheumatoid arthritis; treatment.

Conflict of interest statement

Competing interests: None declared.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. Smolen JS, et al. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Review.
Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis.
Oiwa H. Oiwa H. Ann Rheum Dis. 2018 Jul;77(7):e35. doi: 10.1136/annrheumdis-2017-212206. Epub 2017 Aug 22. Ann Rheum Dis. 2018. PMID: 28830885 No abstract available.